The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.00
Bid: 295.00
Ask: 299.00
Change: -8.00 (-2.63%)
Spread: 4.00 (1.356%)
Open: 292.00
High: 298.00
Low: 292.00
Prev. Close: 304.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Hutchmed in Macau boost; UP Global success in Germany

Tue, 01st Mar 2022 20:32

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Receives approval to market fruquintinib, an inhibitor of vascular endothelial growth factor receptors, in Macau. Drugs of this type are often used to treat cancer.

----------

UP Global Sourcing Holdings PLC - Oldham, Greater Manchester-based consumer brands owner - Petra brand receives first "substantial" order from a German hypermarket retailer. "Petra, the group's recently acquired German kitchen electrical brand, is well recognised in the German market and enjoys a reputation for quality and design innovation," UP Global says. Deal is worth EUR1 million.

----------

JPMorgan Russian Securities PLC - Russia-focused investor - Says 49% of portfolio comprises of locally-listed stocks it is currently not allowed to trade in due to restrictions. Holds shares in Russian state-backed VTB Bank amounting to 1.9% of investor's portfolio. Company manager monitoring impact of sanctions and also waives management fee. Will not buyback shares during uncertain market conditions and says sanctions restrict ability to pay further dividends. "It remains the company's intention to resume quarterly dividend payments once circumstances permit," JPMorgan Russian says.

----------

Puma VCT 13 PLC - venture capital trust - Exercises over-allotment facility linked with GBP25 million fundraise. To raise further GBP5 million.

----------

Bango PLC - Cambridge-based mobile commerce company - Begins trading on OTC Markets Group's OTCQX Best Market. "Trading on OTCQX will further increase the visibility and accessibility of Bango to North American investors. OTCQX supports more transparent quotation and trading of Bango ordinary shares in US dollars during trading hours in the United States, allowing easier access for investors who prefer securities that trade domestically in US dollars," Bango adds.

----------

Omega Diagnostics Group PLC - Alva, Scotland-based medical diagnostics - Says total amount raised from fundraise is GBP5.5 million. It had planned to raise up to GBP7 million.

----------

DeepMatter Group PLC - Glasgow, Scotland-based digital chemistry data company - Signs collaboration deal with Standigm Inc, a workflow artificial intelligence drug discovery company, based in South Korea. "The first stage of the agreement is expected to generate revenues of GBP233,000. The group is now actively working towards broadening the scope of the agreement in the three-year term," DeepMatter says. "DeepMatter will provide access to its proprietary data and algorithms via its unique data and laboratory integration platform."

----------

7digital Group PLC - London-based music licensing provider - Signs deal with existing B2B music streaming service customer worth at least EUR2.2 million over three-year period. "The company has been providing services to the customer since 2016, with contract renewals on an annual basis. This latest contract expands the relationship to a long-term agreement, providing greater visibility over revenue. The company also expects the value of the contract to increase as the fast-growing customer seeks to expand its brand into further territories, which would require further licence agreements with 7digital," 7digital says.

----------

Mobile Streams PLC - London-based mobile content provider - Says monthly revenue now exceeds USD150,000. "In addition, the company has commenced the process of uploading its content, including Esports, to the Huawei App gallery and anticipates once successful these will be made available across the Huawei handset user base," Mobile Streams adds.

----------

Hardide PLC - Oxfordshire-based advanced surface coating technology developer - Delivers first production set of coated turbine blades for Ansaldo Energia Spa, a manufacturer of steam and gas turbines. "These blades are to be installed in advanced gas turbine engines with high operational flexibility that cut CO2 emissions and operational costs in a very demanding market. More orders for this application are expected to be placed during 2022," Hardide adds.

----------

Getech Group PLC - Leeds-based provider of geoscience data - Wins GBP1.2 million deals for its geoscience data and energy software products. "The contracts, which include annual and multi-year licences with new and existing customers, add to Getech's recurring revenue and orderbook," company says.

----------

Journeo PLC - Leicestershire-based transport information systems and technical services - Gets GBP2.1 million order from City of Edinburgh to upgrade real-time outdoor passenger display systems. "The purchase order includes the supply and support of over 400 optically bonded new displays as part of the second phase of a 5 year GBP4.8 million services and support contract," Journeo says.

----------

AFC Energy PLC - Cranleigh, England-based hydrogen power generation technologies provider - Says it and partner Acciona agree to deploy AFC's first hybrid fuel cell system in Spain.

----------

Phoenix Copper Ltd - British Virgin Islands-based base and precious metals production and exploration company - Under environmental, social and governance plans, Phoenix is to create the Konnex Community Advisory Team. This is to build "meaningful relationships" in communities near Empire State mine in Idaho, US.

----------

Beowulf Mining PLC - developing Kallak iron ore mine in Sweden and Aitolampi graphite mine in Finland - Invests further GBP200,000 in Vardar Minerals Ltd. Increases stake to 51% from 49%. Also notes talks with Vardar's management for final plan for drilling, including at Wolf Mountain, which has lead and zinc targets. "Drilling could start in the next 1-2 months and Beowulf would provide the funding," Beowulf adds.

----------

Mila Resources PLC - London-based gold company focused on Australia - Second drill hole at Kathleen Valley, Australia hosts sulphides akin to adjacent Bellevue gold discoveries. "Drilling continues to define a wide coherent zone of mineralisation which is open at depth and maintains a very-linear consistent zone," Mila says.

----------

88 Energy Ltd - Australia-based oil explorer in US state of Alaska - Says mobilisation of Arctic Fox rig to Merlin-2 appraisal well drilling location is now complete. "Pre-spud operations are continuing and now entering the final phase. The Merlin-2 spud date is scheduled for the week commencing 7 March 2022," 88 adds.

----------

Cloudbreak Discovery PLC - London-based natural resource project generator - Raises GBP1.5 million in share placing, to advance various project generation initiatives and for working-capital purposes. Cloudbreak places 20 million shares at 7.50p each, representing a 20% discount to Monday's closing price of 10.22p.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2023 13:47

Hutchmed China completes enrolment for solveplenib clinical trial

(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for 'ESLIM-01', a pivotal phase 3 clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (ITP) in China.

Read more
3 Jan 2023 10:28

Hutchmed completes patient enrolment for ITP clinical trial in China

(Alliance News) - Hutchmed (China) Ltd on Tuesday said it has completed patient enrolment for its clinical trial exploring potential treatment therapies for adults with primary immune thrombocytopenia in China.

Read more
19 Dec 2022 19:29

TRADING UPDATES: Tekcapital's MicroSalt plans IPO in 2023

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
15 Nov 2022 11:30

Hutchmed refocuses strategy away from early-stage studies

(Sharecast News) - Hutchmed China updated the market on its strategy on Tuesday, following an "in-depth evaluation" of the business.

Read more
15 Nov 2022 10:52

Hutchmed China to shift strategy toward advanced assets in pipeline

(Alliance News) - Hutchmed (China) Ltd announced on Tuesday it will shift focus towards its most advanced assets from its internal developed pipeline, following an evaluation of the business.

Read more
14 Nov 2022 16:55

LONDON MARKET CLOSE: Europe ends higher but New York struggles

(Alliance News) - European equities surrendered some afternoon gains but made a bright start to the week on Monday, shaking off hawkish noise from the US Federal Reserve, while investors waited with bated breath for the outcome of talks between the leaders of the world's two leading economies.

Read more
14 Nov 2022 14:20

IN BRIEF: Hutchmed sees positive results for gastric cancer drug

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical company - Reports positive top-line results for its gastric cancer treatment fruquintinib, when combined with paclitaxel. Explains the drug met one of its primary endpoints of statistically significant improvement in progression-free survival during a phase-three study in 703 patients, which the firm says is "clinically meaningful". Fruquintinib also shows a "statistically significant improvement" in secondary endpoints including objective response rate, disease control rate, and improved duration of response, Hutchmed adds. The study looked at patients with advanced gastric or gastroesophageal junction adenocarcinoma, a type of cancer.

Read more
14 Nov 2022 10:27

AIM WINNERS & LOSERS: Hutchmed up on positive results for cancer drug

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
14 Nov 2022 09:40

Hutchmed reports positive results from recent fruquintinib study

(Sharecast News) - Hutchmed China announced initial results from the 'FRUTIGA' phase 3 study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma on Monday.

Read more
27 Oct 2022 14:27

IN BRIEF: Hutchmed begins phase II/III trial of fruquintinib

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Begins randomised, open-label, active-controlled phase II/III trial of fruquintinib combination with sintilimab in China. The trial will explore the combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma - the most common type of kidney cancer. The first patient in China received the dose on Thursday, it says.

Read more
10 Oct 2022 10:24

Hutchmed begins sovleplenib trial for anaemia treatment in China

(Alliance News) - Hutchmed China Ltd on Monday said it has begun a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmune haemolytic anaemia in China.

Read more
8 Sep 2022 11:02

Hutchmed posts positive results for CRC cancer treatment

(Alliance News) - Hutchmed China Ltd on Thursday said that its fruquintinib treatment reduced risk of death by 34% in metastatic colorectal cancer patients.

Read more
9 Aug 2022 10:04

Hutchmed notes dosing of first participant in IMG-004 study

(Alliance News) - Hutchmed China Ltd on Tuesday said it has dosed its first participant in its global phase one trial of IMG-004.

Read more
8 Aug 2022 12:42

Hutchmed upbeat on latest study results for colorectal cancer treatment

(Sharecast News) - Hutchmed China announced on Monday that the "pivotal" global phase three trial evaluating the investigational use of 'fruquintinib' met its primary endpoint of overall survival in patients with advanced, refractory metastatic colorectal cancer (CRC).

Read more
8 Aug 2022 11:32

UPDATE: Hutchmed, AstraZeneca move lung cancer drug to phase 3 trial

(Alliance News) - Hutchmed China Ltd and AstraZeneca PLC on Monday said preliminary results from the Savannah phase 2 trial showed a promising objective response rate, and has moved the drug into phase 3 trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.